Wed, February 21, 2024

Stephen Willey Maintained (ABCL) at Strong Buy with Decreased Target to $17 on, Feb 21st, 2024

Stephen Willey of Stifel, Maintained "AbCellera Biologics Inc." (ABCL) at Strong Buy with Decreased Target from $21 to $17 on, Feb 21st, 2024.

Stephen has made no other calls on ABCL in the last 4 months.



There is 1 other peer that has a rating on ABCL. Out of the 1 peers that are also analyzing ABCL, 0 agree with Stephen's Rating of Hold.



This is the rating of the analyst that currently disagrees with Stephen


  • Scott Schoenhaus of "Keybanc" Initiated at Buy and Held Target at $6 on, Tuesday, December 5th, 2023